ASTH Earnings

ASTH reported its FY2025Q4 earnings on 2026-03-02, showcasing a revenue of 950.53M against an estimate of 923.83M, resulting in a 2.89% surprise. The EPS was 0.54, surpassing the expected 0.15 by 260%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ASTH's FY2025Q4 earnings announcement on 2026-03-02, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ASTH's stock price tends to shift by an average of -0.49% in the 10 days leading up to earnings and -3.69% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ASTH's annual revenue to reach 928.03M, while the EPS is projected at 0.17. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.08% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ASTH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.08%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ASTH's stock price typically moves by -0.49% in the 10 days before its earnings and -3.69% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.17 and revenue of 928.03M.

The earnings call indicates positive sentiment with strong revenue guidance for 2025, optimistic medium-term EBITDA projections, and a strategic partnership with Intermountain Health. Despite a minor EBITDA reduction due to timing delays, the company's focus on deleveraging and synergy savings, along with stable cash flow and improving Medicaid trends, are favorable. The Q&A section did not reveal significant negative concerns, and the partnership and revenue growth are expected to positively impact the stock price.